Format

Send to

Choose Destination
Int J Artif Organs. 1999 Dec;22(12):798-804.

Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension.

Author information

1
Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.

Abstract

The efficacy, safety, and pharmacokinetics of bisoprolol were investigated following oral administration once daily for 12 weeks in hyperreninemic patients with dialysis-refractory hypertension. Mean blood pressure rapidly fell from 132 to 112 mmHg in the 5.0-mg/day (n = 6) and from 142 to 128 mmHg in the 2.5-mg/day patients (n = 5), which were accompanied by a fall in plasma renin activity. On nondialysis days, Cmax and T1/2 were significantly higher in patients than in healthy control subjects. However, Cmax in the 2.5-mg/day patients was almost equal to that in healthy control subjects receiving 5.0 mg/day of bisoprolol. Plasma bisoprolol was dialyzable. During the course of the study, dialysis hypotension and bradycardia occurred in two patients receiving 5.0 mg/day of bisoprolol. In conclusion, a daily dose of 2.5 mg bisoprolol seems to be an adequate and relatively effective dose in our patients with dialysis-refractory hypertension.

PMID:
10654875
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center